CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc. is an early-stage drug development partner offering research models and non-clinical development services. The company organizes its operations across three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Its core offerings include purpose-bred rodents and larger research models, genetically engineered model creation, diagnostic testing, and cellular materials for research and therapies. It also delivers integrated drug discovery, bioanalytical support, safety pharmacology, specialized toxicology, pathology evaluations, and quality control testing such as endotoxin and microbial detection. The company serves global pharmaceutical and biotechnology corporations, academic institutions, contract research organizations, hospitals, and government agencies, along with chemical, consumer product, and medical device manufacturers.

The company operates more than 120 facilities across more than 20 countries, with research model production locations positioned across North America, Europe, and Asia. Charles River Laboratories International, Inc. maintains its corporate headquarters in Wilmington, Massachusetts.

Summary of the business section of Charles River Laboratories International's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 27, 2025, we had approximately 19,700 employees (including approximately 2,400 science professionals with advanced degrees, including Ph.D.s, D.V.M.s and M.D.s).”